Share This Author
A phase 3 trial of bevacizumab in ovarian cancer.
In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial
- B. Oh, P. Butow, D. Rosenthal
- Medicine, PsychologyAnnals of oncology : official journal of the…
- 30 October 2009
It is indicated that MQ can improve cancer patients’ overall QOL and mood status and reduce specific side-effects of treatment and may also produce physical benefits in the long term through reduced inflammation.
Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial
Results suggest that MQ benefits cancer patients’ self-reported CF, QOL, and inflammation, and a larger randomized controlled trial is planned.
Clinical Trials in Recurrent Ovarian Cancer
- M. Friedlander, E. Trimble, G. Stuart
- MedicineInternational Journal of Gynecologic Cancer
- 22 March 2011
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010, and the consensus reached regarding 4 questions including what is the role of cytoreductive surgery for recurrent ovarian cancer was reported.
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
When given orally once daily for 5 days, temozolomide was well tolerated and produced a non-cumulative, transient myelosuppression, the most common non-haematological toxicities were mild to moderate nausea and vomiting.
Nutritional Assessment in Cancer: Comparing the Mini-Nutritional Assessment (MNA) With the Scored Patient-Generated Subjective Global Assessment (PGSGA)
Both tools were able to correctly classify patients as malnourished, although the MNA lacks specificity, and the PGSGA should be the tool of choice for nutritional assessment in cancer patients.
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.
- N. Leighl, H. Shepherd, M. Tattersall
- MedicineJournal of clinical oncology : official journal…
- 20 May 2011
This randomized trial of a decision aid in advanced cancer showed that its use in advanced colorectal cancer improved patient understanding of prognosis, treatment options, risks, and benefits without increasing anxiety.
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug
An excretion balance and pharmacokinetic study was conducted in cancer patients with solid tumors who received a single oral dose of capecitabine, finding that the dose was almost completely recovered in the urine over a period of 7 days after drug administration.
Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study.
- J. Vardy, H. Dhillon, I. Tannock
- Medicine, PsychologyJournal of clinical oncology : official journal…
- 2 November 2015
Patients with CRC had substantially more cognitive impairment at every assessment than HCs, with no significant added effect of chemotherapy.